Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease colorectal cancer
Phenotype C0021831|bowel disease
Sentences 42
PubMedID- 22522090 Background & aims: the risk for colorectal cancer (crc) in patients with inflammatory bowel disease (ibd) could have changed over time, with changes in treatment options.
PubMedID- 24407106 Serum inflammatory markers and risk of colorectal cancer in patients with inflammatory bowel diseases.
PubMedID- 24076060 Background & aims: although restorative proctocolectomy with ileal pouch-anal anastomosis (ipaa) substantially reduces the risk of colorectal cancer in patients with inflammatory bowel disease (ibd), subsequent pouch neoplasia can develop.
PubMedID- 25337558 Various chemopreventive agents have been clearly shown to reduce the risk of colorectal adenoma and cancer in the general population and the problems associated with colonoscopic surveillance have led to increasing interest in utilising chemopreventive strategies to reduce the risk of colorectal cancer in patients with inflammatory bowel disease as well.30 because colitis-associated cancers arose in the setting of chronic inflammation, during which “inflammation-dysplasia-carcinoma sequence” prevails and anti-inflammatory agents can prevent carcinogenesis, we have published data regarding chemoprevention of colitic cancer using infliximab31 and 8-ohdg.32 apart from colitic cancer, colorectal carcinogenesis is also based on a multi-step process characterized by molecular and cellular alterations that result in an identifiable precursor lesion, ie, the adenomatous polyp.33 the transition from normal mucosa to adenoma and its subsequent progression to carcinoma are protracted events that offer opportunities for preventive interventions.
PubMedID- 23619008 The risk of colorectal cancer in patients with inflammatory bowel diseases in finland: a follow-up of 20 years.
PubMedID- 25531497 colorectal cancer in patients with inflammatory bowel disease: the true impact of the risk.
PubMedID- 23264896 An exaggerated inflammatory response has been reported to increase the risk of colorectal cancer in patients with inflammatory bowel disease (ibd), ulcerative colitis (uc) or crohn’s disease.
PubMedID- 23401648 Similarly, aminosalicylates such as sulfasalazine, mesalazine, and others have been shown to reduce the risk for colitis-associated colorectal cancer (cac) in patients with inflammatory bowel disease [5].
PubMedID- 22164923 This position paper of the section of gastrointestinal oncology of the israeli gastroenterological association recommends specific guidelines for colorectal cancer surveillance in patients with inflammatory bowel disease.
PubMedID- 21085072 Surveillance for colorectal cancer in patients with inflammatory bowel disease.
PubMedID- 25557336 Colonoscopy surveillance for dysplasia and colorectal cancer in patients with inflammatory bowel disease.
PubMedID- 25157526 The risk for developing dysplasia and colorectal cancer in patients with longstanding inflammatory bowel disease (ibd) involving the colon is well documented.
PubMedID- 21820431 In particular, decreased e-cadherin-mediated adhesion during inflammatory bowel disease and loss of ephb/ephrin-b-mediated compartmentalization in colorectal cancer have recently emerged as key players of these prevalent pathologies.
PubMedID- 22122774 The risk of developing colorectal cancer is increased in patients with inflammatory bowel disease (ibd).
PubMedID- 22398065 Background: the increased risk of colorectal cancer (crc) in patients with inflammatory bowel disease (ibd) is well established.
PubMedID- 21789787 Interestingly, a recent study revealed that ntn1 expression is selectively up-regulated in colorectal cancers associated with bowel diseases.
PubMedID- 23709348 The risk of developing colorectal cancer (crc) increases in patients with inflammatory bowel disease.
PubMedID- 23086115 Background: differentiating surveillance from non-surveillance colonoscopy for colorectal cancer in patients with inflammatory bowel disease (ibd) using electronic medical records (emr) is important for practice improvement and research purposes, but diagnosis code algorithms are lacking.
PubMedID- 24760232 The possibility of field cancerization in the colon was first suggested by the increased occurrence of flat dysplasia and colorectal cancer in individuals with inflammatory bowel disease.
PubMedID- 24463282 The risk of developing colorectal cancer is increased in patients with inflammatory bowel disease.
PubMedID- 24788218 Background: active colitis impairs neoplasia detection during colonoscopic surveillance for colorectal cancer in patients with inflammatory bowel disease.
PubMedID- 24117071 Inflammatory bowel disease increases the risks of human colorectal cancer.
PubMedID- 23169309 Overview of molecular pathways in inflammatory bowel disease associated with colorectal cancer development.
PubMedID- 23664897 Epidemiological studies demonstrate an increased risk of colorectal cancer in patients with inflammatory bowel disease (ibd).
PubMedID- 22523611 colorectal cancer surveillance in patients with inflammatory bowel disease: what is new.
PubMedID- 23407916 Management of colorectal cancer in patients with inflammatory bowel disease.
PubMedID- 25531498 This review summarizes the advances and current standards of colorectal cancer prevention in patients with inflammatory bowel disease, fap and lynch syndrome.
PubMedID- 22228163 Patients: colorectal cancer cases associated with inflammatory bowel disease diagnosed between 1990 and 2006 were selected in a nationwide pathology archive.
PubMedID- 25230162 colorectal cancer surveillance in patients with inflammatory bowel disease and primary sclerosing cholangitis: an economic evaluation.
PubMedID- 24280874 Background: colitis-associated colorectal cancer affects individuals with inflammatory bowel disease (ibd) more often and earlier than cancer in the general population.
PubMedID- 21386829 A classic paradigm is the enhanced risk of colorectal cancer (crc) in patients with inflammatory bowel disease (ibd).
PubMedID- 25041864 A rule for determining risk of colorectal cancer in patients with inflammatory bowel disease.
PubMedID- 25113042 Chromoendoscopy for colorectal cancer surveillance in patients with inflammatory bowel disease.
PubMedID- 19863607 Aim: colorectal cancer is associated with inflammatory bowel disease.
PubMedID- 20670073 In the discussion, characteristics and major risk factors for colorectal cancer in patients with inflammatory bowel disease will be largely reviewed, and current studies will be analyzed in connection with the appearance of neoplasms in patients being treated with biologics.
PubMedID- 24621115 The best surveillance practices for colorectal cancer screening in patients with inflammatory bowel disease remains unclear.
PubMedID- 23251399 In addition, cholecystectomy, inflammatory bowel disease and history of polyps for colorectal cancer; benign prostatic hyperplasia, 5-alpha reductase inhibitors, and number of psa tests for prostate cancer; oophorectomy, use of hormone replacement therapy, and prior use of oral contraceptives for breast cancer.
PubMedID- 20334955 Conclusions: whereas htert immunostaining provides equivocal results, the observation that patients at high risk for colorectal cancer because of long-standing inflammatory bowel disease overexpress htert mrna in non-affected colorectal mucosa suggests its potential usefulness as a biomarker of the risk of malignant transformation.
PubMedID- 22369306 Chronic inflammation plays a pivotal role in the development of colorectal cancer (crc) in patients with inflammatory bowel disease (ibd).
PubMedID- 22919240 colorectal cancer in patients with inflammatory bowel disease: can we predict risk.
PubMedID- 25840920 Molecular alterations of colorectal cancer with inflammatory bowel disease.
PubMedID- 22583410 The risk of developing colorectal cancer increases in patients with inflammatory bowel disease (ibd) and a growing body of evidence shows the critical role of interleukin (il-6) in this process.

Page: 1